insights_auto
Prečo akcie BNTX stúpli 5,32%?
Preskúmať podrobnejšiechevron_right
BNTX:NASDAQ
BioNTech
96,96 USD
arrow_upward
+5,32%(+4,90) 1 d.
96,96 USD
0,00% (0,00)
bedtimePo uzavretí
Zavreté: 9. 10., 16:00:01 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre BNTX…
Otvoriť
92,45 USD
Vysoká
97,40 USD
Nízka
92,30 USD
Trh. kap.
24,36 mld.
Priem. obj.
993,50 tis.
Objem
1,32 mil.
Max. za 52 týž.
123,98 USD
Min. za 52 týž.
79,52 USD
Výnosy na akciu
-7,52 USD
Beta
1,22
Akcie v obehu
251,20 mil.
Počet zamestnancov
8 tis.
Otvoriť
92,45 USD
Vysoká
97,40 USD
Nízka
92,30 USD
Trh. kap.
24,36 mld.
Priem. obj.
993,50 tis.
Objem
1,32 mil.
Max. za 52 týž.
123,98 USD
Min. za 52 týž.
79,52 USD
Výnosy na akciu
-7,52 USD
Beta
1,22
Akcie v obehu
251,20 mil.
Počet zamestnancov
8 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
AD HOC NEWS
·
pred 2 hodinami
BioNTech's 5.4% Friday Rally Came Without a Company Catalyst — and the Insider Trades Kept Coming
Investing.com Nigeria
·
pred 21 hodinami
Form 4 BioNTech SE For: 9 October By Investing.com
Stock Titan
·
pred 1 dňom
Under a trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 36,209 and 27,000 shares.
Benzinga
·
pred 1 dňom
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
Profil
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Informácie o subjekte BioNTech